NASDAQ · Biotechnology

Atossa Therapeutics, Inc. (ATOS) Stock

$2.44 +0.83% NASDAQ: ATOS Healthcare

Valuation

MetricValue
Price$2.44
Market Cap$24.34M
P/E Ratio-0.54
P/B Ratio0.78
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$19.35
52-Week Low$1.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-102.99%
ROA-116.81%
ROCE-146.30%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio5.75

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-21.0M$-28.0M$-31.0M$-28.0M$-37.0M
Net Profit$-21.0M$-27.0M$-30.0M$-26.0M$-35.0M
EPS$-2.70$-3.15$-3.60$-3.00$-4.04
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$141.0M$124.0M$96.0M$76.0M$48.0M
Total Liabilities$3.0M$6.0M$5.0M$5.0M$8.0M
Cash$136.0M$111.0M$88.0M$71.0M$41.0M
Borrowings$0$0$0$0$0

Latest News

ATOS: Raises up to $16.5 Million in Registered Direct Offering Zacks Small Cap Research · Jul 1, 2026 Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire · Jun 12, 2026 Top Midday Decliners MT Newswires · Jun 11, 2026 Atossa Therapeutics Launches $16.5 Million Registered Direct Offering MT Newswires · Jun 11, 2026 Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds PR Newswire · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-21.0M$-21.0M$-21.0M$-30.0M
Investing Cash Flow$0$-5.0M$0$0$0
Financing Cash Flow$44.0M$0$-1.0M$0$0
Net Cash Flow$97.0M$-25.0M$-22.0M$-17.0M$-30.0M
Free Cash Flow$-16.0M$-21.0M$-21.0M$-21.0M$-30.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA0.07
FCF Yield-153.30%
Quick Ratio5.69
Interest Coverage0.00
Return 1Y-82.12%
Return 3Y-86.88%
Return 5Y-96.39%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. is led by CEO Steven C. Quay, employs 15 people, headquartered in US, publicly traded since 2012.

Atossa Therapeutics, Inc. (ATOS) stock trades at $2.44 with a market capitalization of $24.34M. The stock is valued at a price-to-earnings (P/E) ratio of -0.54, price-to-book of 0.78, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.70 and $19.35, and currently trades 87.4% below its 52-week high.

On profitability, Atossa Therapeutics, Inc. generates a return on equity (ROE) of -102.99%, return on capital employed of -146.30%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides